BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28078663)

  • 21. Rhein inhibits angiogenesis and the viability of hormone-dependent and -independent cancer cells under normoxic or hypoxic conditions in vitro.
    Fernand VE; Losso JN; Truax RE; Villar EE; Bwambok DK; Fakayode SO; Lowry M; Warner IM
    Chem Biol Interact; 2011 Jul; 192(3):220-32. PubMed ID: 21457705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of the cochaperone AHA1 regulates heat-shock protein 90 and endothelial NO synthase activation by vascular endothelial growth factor.
    Desjardins F; Delisle C; Gratton JP
    Arterioscler Thromb Vasc Biol; 2012 Oct; 32(10):2484-92. PubMed ID: 22859491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives.
    Boroumand N; Saghi H; Avan A; Bahreyni A; Ryzhikov M; Khazaei M; Hassanian SM
    J Pharm Pharmacol; 2018 Feb; 70(2):151-158. PubMed ID: 28980313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of the 90-kDa heat shock protein (Hsp-90) in CB2 cannabinoid receptor-mediated cell migration: a new role of Hsp-90 in migration signaling of a G protein-coupled receptor.
    He F; Qiao ZH; Cai J; Pierce W; He DC; Song ZH
    Mol Pharmacol; 2007 Nov; 72(5):1289-300. PubMed ID: 17698952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.
    Tomcik M; Zerr P; Pitkowski J; Palumbo-Zerr K; Avouac J; Distler O; Becvar R; Senolt L; Schett G; Distler JH
    Ann Rheum Dis; 2014 Jun; 73(6):1215-22. PubMed ID: 23661493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
    Karkoulis PK; Stravopodis DJ; Voutsinas GE
    Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
    Proia DA; Bates RC
    Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models.
    Lin SF; Lin JD; Hsueh C; Chou TC; Yeh CN; Chen MH; Wong RJ
    Oncotarget; 2017 Jun; 8(25):41294-41304. PubMed ID: 28476040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
    Breinig M; Mayer P; Harjung A; Goeppert B; Malz M; Penzel R; Neumann O; Hartmann A; Dienemann H; Giaccone G; Schirmacher P; Kern MA; Chiosis G; Rieker RJ
    Clin Cancer Res; 2011 Apr; 17(8):2237-49. PubMed ID: 21372220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent updates on the development of ganetespib as a Hsp90 inhibitor.
    Choi HK; Lee K
    Arch Pharm Res; 2012 Nov; 35(11):1855-9. PubMed ID: 23212626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
    Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exogenous hydrogen sulfide exerts proliferation, anti-apoptosis, angiopoiesis and migration effects via activating HSP90 pathway in EC109 cells.
    Lei Y; Zhen Y; Zhang W; Sun X; Lin X; Feng J; Luo H; Chen Z; Su C; Zeng B; Chen J
    Oncol Rep; 2016 Jun; 35(6):3714-20. PubMed ID: 27108782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
    Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
    Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
    Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
    Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC.
    Misso G; Giuberti G; Lombardi A; Grimaldi A; Ricciardiello F; Giordano A; Tagliaferri P; Abbruzzese A; Caraglia M
    J Cell Physiol; 2013 Jan; 228(1):130-41. PubMed ID: 22566192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
    Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
    Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.
    Cheng W; Ainiwaer A; Xiao L; Cao Q; Wu G; Yang Y; Mao R; Bao Y
    Mol Med Rep; 2015 Aug; 12(2):2451-6. PubMed ID: 25955495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
    Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
    Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.